NIH Will Not “March-In” On Pfizer’s Xalatan
This article was originally published in The Pink Sheet Daily
Executive Summary
Similar to its decision in the Norvir case, NIH says availability, not price, is test of whether the agency can “march-in” on a company’s exclusivity.